## Corrigendum to "PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis" [EBioMedicine 40 (2019) 290-304]

Cristian Rodriguez-Aguayo,<sup>a,b,1</sup> Emine Bayraktar,<sup>a,c,1</sup> Cristina Ivan,<sup>a,b</sup> Burcu Aslan,<sup>a,b</sup> Junhua Mai,<sup>d</sup> Guangan He,<sup>a</sup> Lingegowda S. Mangala,<sup>b,g</sup> Dahai Jiang,<sup>b,g</sup> Archana S. Nagaraja,<sup>g</sup> Bulent Ozpolat,<sup>a</sup> Arturo Chavez-Reyes,<sup>e</sup> Mauro Ferrari,<sup>d</sup> Rahul Mitra,<sup>b,g</sup> Zahid H. Siddik,<sup>a</sup> Haifa Shen,<sup>d</sup> Xianbin Yang,<sup>h</sup> Anil K. Sood,<sup>b,f,g</sup> and Gabriel Lopez-Berestein<sup>a,b,f</sup>\*

<sup>a</sup>Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA <sup>b</sup>Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

<sup>c</sup>Department of Medical Biology, Faculty of Medicine, University of Gaziantep, Gaziantep 27310, Turkey

<sup>d</sup>Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA

<sup>e</sup>Centro de Investigación y Estudios Avanzados del IPN, Unidad Monterrey, Apodaca, NL, CP. 66600, Mexico

<sup>f</sup>Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

<sup>9</sup>Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

The authors noticed that in Figure 6B, the TUNEL staining panel for the "PTGER3 siRNA" group was inadvertently

duplicated in the next position for the group of "2'F-PS2-PTGER3 siRNA". Below is the corrected version of

Figure 6B TUNEL staining panels with a new representative image for the 2'F-PS2-PTGER3 siRNA group. This

<sup>h</sup>AM Biotechnologies LLC, 12521 Gulf Freeway, Houston, TX 77034, USA


## eBioMedicine 2022;83: 104194

Published online xxx https://doi.org/10.1016/j. ebiom.2022.104194

1

The authors apologize for any inconvenience caused.

change does not affect the results or conclusions.



**Figure 6B.** Immunohistochemical analysis of Ki-67, CD-31, TUNEL and cisplatin uptake in mouse xenograft A2780-CP20 and OVCAR5 cisplatin-resistant tumors. The analysis showed that treatment with MSV-DOPC-PTGER3-siRNA or DOPC-2'-F-PS2-PTGER3 and/or combination with cisplatin reduced proliferation and angiogenesis and increased apoptosis in vivo. (A, B). Tumor tissue platinum uptake showed significantly greater accumulation of cisplatin in DOPC-PTGER3 siRNA and with greater uptake for DOPC-2'-F-PS2-PTGER3 in combination with cisplatin (C). Means ± SEM are shown. \*, P b .05; \*\*, P b .01; \*\*\*, P b .001. 302 C. Rodriguez-Aguayo et al. / EBioMedicine 40 (2019) 290-304.

DOI of original article: http://dx.doi.org/10.1016/j.ebiom.2018.11.045 \*Corresponding author.

E-mail address: glopez@mdanderson.org (G. Lopez-Berestein).

© 2022 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

<sup>1</sup> These authors contributed equally to this work.

